These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 34631945)

  • 1. Does MDS-UPDRS Provide Greater Sensitivity to Mild Disease than UPDRS in De Novo Parkinson's Disease?
    Tosin MHS; Stebbins GT; Comella C; Patterson CG; Hall DA;
    Mov Disord Clin Pract; 2021 Oct; 8(7):1092-1099. PubMed ID: 34631945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does the MDS-UPDRS provide the precision to assess progression in early Parkinson's disease? Learnings from the Parkinson's progression marker initiative cohort.
    Regnault A; Boroojerdi B; Meunier J; Bani M; Morel T; Cano S
    J Neurol; 2019 Aug; 266(8):1927-1936. PubMed ID: 31073716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan.
    Goetz CG; Fahn S; Martinez-Martin P; Poewe W; Sampaio C; Stebbins GT; Stern MB; Tilley BC; Dodel R; Dubois B; Holloway R; Jankovic J; Kulisevsky J; Lang AE; Lees A; Leurgans S; LeWitt PA; Nyenhuis D; Olanow CW; Rascol O; Schrag A; Teresi JA; Van Hilten JJ; LaPelle N
    Mov Disord; 2007 Jan; 22(1):41-7. PubMed ID: 17115387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gender-, age-, and race/ethnicity-based differential item functioning analysis of the movement disorder society-sponsored revision of the Unified Parkinson's disease rating scale.
    Goetz CG; Liu Y; Stebbins GT; Wang L; Tilley BC; Teresi JA; Merkitch D; Luo S
    Mov Disord; 2016 Dec; 31(12):1865-1873. PubMed ID: 27943473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results.
    Goetz CG; Tilley BC; Shaftman SR; Stebbins GT; Fahn S; Martinez-Martin P; Poewe W; Sampaio C; Stern MB; Dodel R; Dubois B; Holloway R; Jankovic J; Kulisevsky J; Lang AE; Lees A; Leurgans S; LeWitt PA; Nyenhuis D; Olanow CW; Rascol O; Schrag A; Teresi JA; van Hilten JJ; LaPelle N;
    Mov Disord; 2008 Nov; 23(15):2129-70. PubMed ID: 19025984
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Using Movement Disorder Society Unified Parkinson's Disease Rating Scale Parts 2 and 3 Simultaneously: Combining the Patient Voice with Clinician Ratings.
    Guo Y; Goetz CG; Stebbins GT; Mestre TA; Luo S
    Mov Disord; 2023 Mar; 38(3):453-463. PubMed ID: 36621935
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predicting the Progression of Parkinson's Disease MDS-UPDRS-III Motor Severity Score from Gait Data using Deep Learning.
    Zia Ur Rehman R; Rochester L; Yarnall AJ; Del Din S
    Annu Int Conf IEEE Eng Med Biol Soc; 2021 Nov; 2021():249-252. PubMed ID: 34891283
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between the non-motor items of the MDS-UPDRS and Quality of Life in patients with Parkinson's disease.
    Skorvanek M; Rosenberger J; Minar M; Grofik M; Han V; Groothoff JW; Valkovic P; Gdovinova Z; van Dijk JP
    J Neurol Sci; 2015; 353(1-2):87-91. PubMed ID: 25918077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Item Response Theory Analysis of the MDS-UPDRS Motor Examination: Tremor vs. Nontremor Items.
    Tosin MHS; Goetz CG; Luo S; Choi D; Stebbins GT
    Mov Disord; 2020 Sep; 35(9):1587-1595. PubMed ID: 32469456
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progression of MDS-UPDRS Scores Over Five Years in De Novo Parkinson Disease from the Parkinson's Progression Markers Initiative Cohort.
    Holden SK; Finseth T; Sillau SH; Berman BD
    Mov Disord Clin Pract; 2018; 5(1):47-53. PubMed ID: 29662921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Calibration of unified Parkinson's disease rating scale scores to Movement Disorder Society-unified Parkinson's disease rating scale scores.
    Goetz CG; Stebbins GT; Tilley BC
    Mov Disord; 2012 Sep; 27(10):1239-42. PubMed ID: 22886777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Parkinson's disease severity levels and MDS-Unified Parkinson's Disease Rating Scale.
    Martínez-Martín P; Rodríguez-Blázquez C; Mario Alvarez ; Arakaki T; Arillo VC; Chaná P; Fernández W; Garretto N; Martínez-Castrillo JC; Rodríguez-Violante M; Serrano-Dueñas M; Ballesteros D; Rojo-Abuin JM; Chaudhuri KR; Merello M
    Parkinsonism Relat Disord; 2015 Jan; 21(1):50-4. PubMed ID: 25466406
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Item Response Model Adaptation for Analyzing Data from Different Versions of Parkinson's Disease Rating Scales.
    Gottipati G; Berges AC; Yang S; Chen C; Karlsson MO; Plan EL
    Pharm Res; 2019 Jul; 36(9):135. PubMed ID: 31317279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-World Nonmotor Changes in Patients with Parkinson's Disease and Motor Fluctuations: J-FIRST.
    Watanabe H; Saiki H; Chiu SW; Yamaguchi T; Kashihara K; Tsuboi Y; Nomoto M; Hattori N; Maeda T; Shimo Y;
    Mov Disord Clin Pract; 2020 May; 7(4):431-439. PubMed ID: 32373660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessing the relationship between non-motor symptoms and health-related quality of life in Parkinson's disease: a retrospective observational cohort study.
    Ueno T; Kon T; Haga R; Nishijima H; Arai A; Tomiyama M
    Neurol Sci; 2020 Oct; 41(10):2867-2873. PubMed ID: 32328832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validation of the Hebrew version of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale.
    Zitser J; Peretz C; Ber David A; Shabtai H; Ezra A; Kestenbaum M; Brozgol M; Rosenberg A; Herman T; Balash Y; Gadoth A; Thaler A; Stebbins GT; Goetz CG; Tilley BC; Luo ST; Liu Y; Giladi N; Gurevich T
    Parkinsonism Relat Disord; 2017 Dec; 45():7-12. PubMed ID: 28965872
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can Gait Features Help in Differentiating Parkinson's Disease Medication States and Severity Levels? A Machine Learning Approach.
    Chatzaki C; Skaramagkas V; Kefalopoulou Z; Tachos N; Kostikis N; Kanellos F; Triantafyllou E; Chroni E; Fotiadis DI; Tsiknakis M
    Sensors (Basel); 2022 Dec; 22(24):. PubMed ID: 36560313
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship of Movement Disorders Society-Unified Parkinson's Disease Rating Scale Nonmotor Symptoms to Cognitive Functioning in Patients with Parkinson's Disease.
    Bernard BA; Carns D; Stebbins GT; Goldman JG; Goetz CG
    Mov Disord Clin Pract; 2020 Apr; 7(3):279-283. PubMed ID: 32258225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Movement disorder society unified Parkinson disease rating scale experiences in daily living: longitudinal changes and correlation with other assessments.
    Lang AE; Eberly S; Goetz CG; Stebbins G; Oakes D; Marek K; Ravina B; Tanner CM; Shoulson I;
    Mov Disord; 2013 Dec; 28(14):1980-6. PubMed ID: 24123383
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative mobility measures complement the MDS-UPDRS for characterization of Parkinson's disease heterogeneity.
    Hill EJ; Mangleburg CG; Alfradique-Dunham I; Ripperger B; Stillwell A; Saade H; Rao S; Fagbongbe O; von Coelln R; Tarakad A; Hunter C; Dawe RJ; Jankovic J; Shulman LM; Buchman AS; Shulman JM
    Parkinsonism Relat Disord; 2021 Mar; 84():105-111. PubMed ID: 33607526
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.